H2020Индивидуална стипендия2021–2023

MiRepair · MiRNAs as therapeutics for neurorepair in Multiple Sclerosis

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2021-06-01 → 2023-05-31
Финансиране от ЕС: 184 591 €
Участници: 1
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

МикроРНК молекулите се изследват като средство за стимулиране на възстановяването на миелиновите обвивки около нервните клетки при разсеяна склероза. Това е важно, защото настоящите терапии не могат да възстановят уврежданията в мозъка и да спрат прогресивното нарастване на инвалидността.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

MiRNAs as therapeutics for neurorepair in Multiple Sclerosis

Multiple sclerosis (MS) is a chronic complex neurological disease of the central nervous system (CNS), which affects 2.3 million people worldwide. One of the main pathological characteristics of multiple sclerosis is demyelination, which involves the injury and loss of myelin sheaths. Myelin is a material that surrounds the part of the neurons that transmit electric impulses from one neuron to the next one (axons). When myelin is intact, axons are insulated, and the electric impulses are transmitted efficiently. However, during demyelination, myelin is damaged, and these nerve impulses are slowed down causing different symptoms in the patients. There is a natural process in the brain, called remyelination, that can partly or completely repair these demyelinated lesions. However, this process is often disrupted in multiple sclerosis patients. The cause of MS is still unknown, but it has been proposed that some genetic and environmental factors are related to MS pathology. microRNAs (miRNAs) are involved in the interaction between these genetic and environmental factors. miRNAs are molecules that can regulate the expression of different genes and have been found altered in several diseases. Specifically in MS, miRNAs have been found to be dysregulated in different tissues and biological fluids. All current disease-modifying therapies in MS are unable to prevent the progressive accumulation of disability and to induce the endogenous repair of the brain. Thus, it is critical that innovative therapeutics that can promote remyelination are designed to address this deficit to treat MS patients. The main research goal of MiRepair project was to identify potential miRNAs related to demyelination and remyelination and to study their therapeutic potential to enhance remyelination in MS. The findings of the project suggests that a specific miRNA and its target genes are potential candidates to enhance remyelination, neurorepair and reduce neuroinflammation in MS.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

I hope to embark my first post-doctoral position, as a MSCA fellow, to identify microRNAs (miRNAs) involved in demyelination/remyelination processes with the final intention of modulating their expression as a therapeutic tool to promote neurorepair in multiple sclerosis (MS). MS is a chronic neurological disease of the central nervous system characterised by primary demyelination. All current disease-modifying therapies are unable to induce neurorepair and to prevent the progressive accumulation of disability from neuronal damage. miRNAs are one epigenetic mechanism involved in the genes-environment interaction that produces the pathology and symptoms in MS. My thesis project consists of describing miRNAs profiles in cerebrospinal fluid and serum of MS patients to exploit their potential role as clinical biomarkers. This project will combine these human miRNA data with robust experimental models in order to identify miRNAs involved in the damage and endogenous repair associated with MS. I will employ ex vivo models to study the biological role of miRNAs during these processes and how their manipulation might enhance neurorepair. The use of hydrogel-scaffolds in combination with miRNA modulators to enhance remyelination will be studied and preclinical MS in vivo models will be used to assess their therapeutic potential. I will work at the “microRNA Inflammation Group” in the Royal College of Surgeons in Ireland (RCSI) under mentorship of Dr Claire McCoy, a leader of MS research in Ireland. Two secondments have been planned in the National University of Ireland, Galway (NUIG) and Queen’s University Belfast (QUB). This fellowship will enable me to upskill in research techniques and expand my transferable skills and competences for a career path for academia or industry in miRNA therapeutics area. This will enhance and contribute to Europe’s competitiveness in R&I supporting European policy objectives as promoting excellence in education and skills development.

Оригинален текст от CORDIS (на английски).

Участници

ROYAL COLLEGE OF SURGEONS IN IRELAND · DUBLIN 2КоординаторИрландия